Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline
Acute therapies continue to report strong growth compared to chronic ones.
This procedure is incidentally the first robotic bariatric surgery in the world to be performed in just three ports
Packaged junk food which is a major component of unhealthy diets is responsible for more deaths worldwide than any other risk factor
Nexviazyme specifically targets the M6P receptor, the key pathway for enzyme replacement therapy, to effectively clear glycogen build-up in muscle cells
Subscribe To Our Newsletter & Stay Updated
